Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome

Alba Navarro-Romero, Anna Vázquez-Oliver, Maria Gomis-González, Carlos Garzón-Montesinos, Rafael Falcón-Moya, Antoni Pastor, Elena Martín-García, Nieves Pizarro, Arnau Busquets-Garcia, Jean Michel Revest, Pier Vincenzo Piazza, Fátima Bosch, Mara Dierssen, Rafael de la Torre, Antonio Rodríguez-Moreno, Rafael Maldonado, Andrés Ozaita

Research output: Contribution to journalArticleResearch

7 Citations (Scopus)

Abstract

© 2019 Elsevier Inc. Intellectual disability is the most limiting hallmark of Down syndrome, for which there is no gold-standard clinical treatment yet. The endocannabinoid system is a widespread neuromodulatory system involved in multiple functions including learning and memory processes. Alterations of this system contribute to the pathogenesis of several neurological and neurodevelopmental disorders. However, the involvement of the endocannabinoid system in the pathogenesis of Down syndrome has not been explored before. We used the best-characterized preclinical model of Down syndrome, the segmentally trisomic Ts65Dn model. In male Ts65Dn mice, cannabinoid type-1 receptor (CB1R) expression was enhanced and its function increased in hippocampal excitatory terminals. Knockdown of CB1R in the hippocampus of male Ts65Dn mice restored hippocampal-dependent memory. Concomitant with this result, pharmacological inhibition of CB1R restored memory deficits, hippocampal synaptic plasticity and adult neurogenesis in the subgranular zone of the dentate gyrus. Notably, the blockade of CB1R also normalized hippocampal-dependent memory in female Ts65Dn mice. To further investigate the mechanisms involved, we used a second transgenic mouse model overexpressing a single gene candidate for Down syndrome cognitive phenotypes, the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). CB1R pharmacological blockade similarly improved cognitive performance, synaptic plasticity and neurogenesis in transgenic male Dyrk1A mice. Our results identify CB1R as a novel druggable target potentially relevant for the improvement of cognitive deficits associated with Down syndrome.
Original languageEnglish
Pages (from-to)92-106
JournalNeurobiology of Disease
Volume125
DOIs
Publication statusPublished - 1 May 2019

Keywords

  • Cannabinoid receptor type-1
  • Cognitive deficits
  • Down syndrome
  • Endocannabinoid system
  • Hippocampus
  • Intellectual disability

Fingerprint Dive into the research topics of 'Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome'. Together they form a unique fingerprint.

Cite this